Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (ABT) is a global healthcare leader driving innovations in medical devices, diagnostics, nutrition, and branded generics. This page provides investors and industry professionals with timely updates on the company’s latest developments, strategic initiatives, and regulatory milestones.
Access Abbott’s official press releases alongside curated analysis of key events impacting its diversified business segments. Track updates across diabetes care technologies, cardiovascular device approvals, diagnostic system launches, and nutritional product expansions. Our repository ensures you stay informed about earnings announcements, partnership agreements, and clinical trial outcomes without speculative commentary.
Bookmark this page for streamlined access to Abbott’s evolving market position and evidence-based insights into its global healthcare solutions. Check regularly for verified updates that matter to your investment research or industry analysis.
Rhea-AI Summary
Abbott (NYSE:ABT) has announced the launch of its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass and good nutrition. The shake contains 30 grams of high-quality protein, 8 essential B vitamins, 4 grams of comfort fiber, 1 gram of sugar, 150 calories, and 25 vitamins and minerals. The product is now available online and at various retailers, catering to adults interested in pursuing weight loss while maintaining muscle health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
-
Rhea-AI Summary
Abbott's partnership with the Emergency Food Bank of Stockton, Calif. has led to encouraging results in delivering healthy meal boxes to people with diabetes. Nutrition educator Alex Marapao emphasizes the use of olive oil in cooking demonstrations, promoting healthy habits to combat diabetes. The mission is to share nutrition education that takes root in the community and grows healthy habits for generations to come.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
-
Rhea-AI Summary
A new study published in the journal Transfusion reveals that Abbott and Blood Centers of America's mixed reality technology for use during blood donation helps ease donors' feelings of anxiety and boosts the likelihood they will return to give blood again. The pilot study examined the experiences of 282 blood donors who tried mixed reality at 54 collection sites in Houston and the Quad Cities area in Iowa and Illinois. 68.4% of donors who reported pre-donation anxiety said the mixed reality experience helped ease their anxiety, and 89.2% of donors who tried mixed reality said they were likely to donate blood again. The mixed reality experience is an immersive digital experience designed to improve the blood donation process, attract new donors, and motivate a younger generation to give blood. It is now available at several donation sites across the country, including in New York, Houston, and the Chicago area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Rhea-AI Summary
Abbott (NYSE: ABT) has launched its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass. The brand is aimed at adults pursuing weight loss, with the first product featuring 30 grams of protein, essential B vitamins, comfort fiber, and 150 calories. The shake is now available online and at various retailers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Abbott (NYSE: ABT) has received FDA approval for the Liberta RC™ deep brain stimulation (DBS) system, the world's smallest rechargeable DBS device with remote programming. It offers the longest time between charges of any DBS technology on the market, requiring only 10 recharge sessions a year for most people. The system features NeuroSphere™ Virtual Clinic, allowing remote communication with doctors, ensuring proper settings and functionality, and receiving new treatment settings without visiting a doctor's office.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary
Abbott announced fourth-quarter sales increase of 1.5 percent, full-year 2023 reported sales decreased by 8.1 percent due to COVID-19 testing-related sales; organic sales growth increased by 11.6 percent. The company projects full-year 2024 organic sales growth to be in the range of 8.0% to 10.0%. The R&D pipeline continues to deliver new products, and the company has regained its market-leading position in the U.S. infant formula market. Abbott's new laboratory automation system, GLP systems Track™, received FDA approval, and the company's Volt™ Pulsed Field Ablation System was used for the first time in humans. Abbott's Tandem Diabetes Care's t:slim X2™ insulin pump is now the first automated insulin delivery system in the U.S. to integrate with Abbott's new FreeStyle Libre® 2 Plus sensor. The company's EPS was $3.26 for full-year 2023 and projects a diluted EPS on a GAAP basis of $3.20 to $3.40 for full-year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
Rhea-AI Summary
Abbott has earned the top overall industry score for 11 years and leads in health access on the global sustainability benchmark DJSI. The company's 2030 Sustainability Plan aims to improve the health of 3 billion people annually by 2030, with a focus on connecting care and technology to put people in control. Abbott also achieved top scores in key social, environmental, and governance categories on the S&P Global Corporate Sustainability Assessment, confirming its position as a leader in sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Abbott (ABT) announces the first global procedures using the Volt Pulsed Field Ablation (PFA) System to treat patients with atrial fibrillation. The system uses high energy electrical pulses to destroy cells causing abnormal heart rhythms, reducing the risk of damaging adjacent tissue. The Volt PFA System is designed to overcome limitations of first-generation PFA systems and provide a more accurate and efficient workflow for physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Abbott (ABT) and Tandem Diabetes Care (TNDM) have announced the integration of the FreeStyle Libre 2 Plus sensor with the t:slim X2 insulin pump in the U.S. This marks the first time that Tandem's Control-IQ technology is compatible with the 15-day continuous glucose monitoring (CGM) sensor, providing a hybrid closed-loop system for users in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
Rhea-AI Summary
Abbott (NYSE: ABT) is set to announce its fourth-quarter 2023 financial results on January 24, 2024, before the market opens. The live webcast of the earnings conference call will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
Abbott Labs
NYSE:ABT
ABT Rankings
ABT Stock Data
227.16B
1.72B
0.54%
79.44%
1.32%
Medical Devices
Pharmaceutical Preparations
United States
ABBOTT PARK